Sangamo was founded in 1995 as Sangamo BioSciences, Inc. in order to research new technologies for genome editing. Employees also rated Sangamo Therapeutics 4.1 out of 5 for work life balance, 4.5 for culture and values and 3.8 for career opportunities. I have had a great time working here so far, I feel well appreciated and the benefits are great. Do shift work. Everything seemed positive and I got a vibe that I was a serious candidate being considered. Pioneering the future of genomic medicine, Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results, Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease, Phase 3 Trial of Investigational Gene Therapy for Hemophilia A has Resumed Dosing, Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated -Gal A Enzyme Activity in Nine Patients, Pfizer and Sangamo Therapeutics Announce Phase 3 Trial of Investigational Gene Therapy for Hemophilia A has Re-opened Recruitment, European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation, First-in-human in vivo genome editing via AAV-zinc finger nucleases for mucopolysaccharidosis I/II and hemophilia B, Regulatory Consideration for the Nonclinical Safety Assessment of Gene Therapies, Poster: STAAR, a Phase 1/2 study of isaralgagene civaparvovec (ST 920) gene therapy in adults with Fabry disease, Presentation: STAAR, a Phase 1/2 study of isaralgagene civaparvovec (ST 920) gene therapy in adults with Fabry disease. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP financial information, to more fully understand our business. Sangamo Therapeutics, Inc. Careers Website www.sangamo.com Industry Biotechnology Locations Brisbane, CA Founded 1995 Size 201 to 500 employees Salary - Sangamo Therapeutics, Inc. How is diversity at Sangamo Therapeutics? Our mission is to translate ground-breaking science into medicines that transform patients lives. The decrease in total operating expenses on a GAAP basis was primarily due to the timing of certain research and development activities. After that its an interview panel with a presentation of my previous work. Favorable. What is the interview process like at Sangamo Therapeutics? Renal Transplant Rejection Received Orphan Medicinal Product Designation from the European Commission; progressed manufacturing and clinical activities ahead of anticipated Q3 dosing. Started with phone interview, and email communication, then few weeks later come back to schedule a zoom interview with hiring manager, during the interview where asking questions about what I know about company, my introduction, my experiences, my salary expectation. Participants should register for, and access, the call using this link. Conference Call to Discuss Third Quarter 2022 Results. - Achieved 78% globotriaosylceramide (Gb3) substrate clearance at 6-months and 77% reduction in urine podocyte loss in one of, BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 21, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to hold a conference call on Wednesday, February 22, 2023 at 4:30 p.m. media@sangamo.com, Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results, https://www.businesswire.com/news/home/20221103005505/en/, Net loss attributable to non-controlling interest, Basic and diluted net loss per share attributable to, Shares used in computing basic and diluted net loss per share attributable to, Cash, cash equivalents, and marketable securities, Presented updated preliminary data from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, our wholly owned gene therapy product candidate for the treatment of Fabry Disease at three separate conferences, most notably at the 29th. Cash, cash equivalents and marketable securities as of June 30, 2022, were $363.7 million, compared to $464.7 million as of December 31, 2021. Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term. I applied through college or university. Available materials will be found on the Sangamo Therapeutics website after the event. American Society of Gene and Cell Therapy (ASGCT) Profiled significant pre-clinical progress across Sangamos innovative pipeline and platform. Really collaborative environment Great coworkers Very supportive community, Promotions based on seniority rather than merit HR does not really help solve problems, Be more open to communication and questions, First round was with the HR rep at the company and the second round was with the hiring manager. It was then followed by individual interviews with different members of the team, To get a job at Sangamo Therapeutics, browse, Overall, 89% of employees would recommend, Work Here? This press release features multimedia. 89% of employees would recommend working at Sangamo Therapeutics to a friend and 75% have a positive outlook for the business. Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 22, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2022 financial results. General high turnover rate in biotech industry applies here as well. There can be no assurance that we and our collaborators will be able to develop commercially viable products. I applied through a recruiter. However, I never hear back from them since then. Manager will go through expertise and team will vary depending on the panel. Pays significantly less than South San Francisco companies. A pivotal data readout is estimated in late 2023 or early 2024. Find out more about salaries and benefits at Sangamo Therapeutics. This is based on 44 anonymously submitted reviews on Glassdoor. Unorganized at best. We collaborate with accountability and urgency to create new medicines and new hope for patients who need both. Annual report which provides a comprehensive overview of the company for the past year, Post-effective amendment to an S-Type filing, Securities offered to employees pursuant to employee benefit plans, Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results, Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease, Sangamo Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast, PHASE 3 TRIAL OF INVESTIGATIONAL GENE THERAPY FOR HEMOPHILIA A HAS RESUMED DOSING, EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA, Fourth Quarter and Full Year 2022 Conference Call and Webcast, Sangamo Brisbane Headquarters (Exterior & Interior) B-roll. Questions asked were appropriate and aimed at confirming the candidate possesses the required skills and would be a good fit into the company. Both sides asked questions and got the answers we need, and after the interview, I was even more excited to join the company. Fabry disease Received endorsement to progress into the Ph1/2 studys expansion phase; continued to recruit patients and activate sites; Phase 3 planning progresses. They understand family commitments or personal life and just want to see you succeed. Barclays Gene Editing & Gene Therapy Summit. I interviewed at Sangamo Therapeutics (New York, NY). Participants should register for, and access, the call using this link. Dosed the second patient in the Phase 1/2 STEADFAST study evaluating TX200, our wholly owned autologous CAR-Treg cell therapy treating patients receiving an HLA-A2 mismatched kidney from a living donor. I had 3 phone/Zoom interviews including with HR and the hiring managers. We are engaging in pivotal study-enabling activities in two of our clinical stage programs and are preparing to complete dosing of the first cohort in our TX200 program, which recently received Orphan Medicinal Product Designation from the European Commission. We have excluded stock-based compensation expense because it is a non-cash expense that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the effects of the evolving COVID-19 pandemic and the impacts of the pandemic and other macroeconomic factors, including as a result of the ongoing conflict between Russia and Ukraine, on the global business environment, healthcare systems and business and operations of Sangamo and our collaborators, including the initiation and operation of clinical trials; the research and development process, including the enrollment, operation and results of clinical trials and the presentation of clinical data; the impacts of clinical trial delays, pauses and holds on clinical trial timelines and commercialization of product candidates, including the risk that any necessary conditions to resume dosing of patients in the Phase 3 AFFINE trial are not met in a timely manner, or at all;the uncertain timing and unpredictable nature of clinical trial results, including the risk that therapeutic effects in the Phase 3 AFFINE trial will not be durable in patients as well as the risk that the therapeutic effects observed in the latest preliminary clinical data from the Phase 1/2 STAAR study and the Phase 1/2 PRECIZN-1 study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civaparvovec or BIVV003, and that the patients withdrawn from ERT will remain off ERT; the unpredictable regulatory approval process for product candidates across multiple regulatory authorities; reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results, including the results of any Phase 3 trial of our product candidates; our limited experience manufacturing biopharmaceutical products, including the risks that we may be unable to maintain compliant manufacturing facilities, build additional facilities and manufacture our product candidates as intended; the potential for technological developments that obviate technologies used by Sangamo; the potential for Sangamo to cease development of the BIVV003 program, whether due to its inability to secure options to advance the program or otherwise;our lack of resources to fully develop, obtain regulatory approval for and commercialize our product candidates; and our ability to achieve expected future financial performance. These risks and uncertainties are described more fully in our Securities and Exchange Commission filings and reports, including in our Annual Report on Form 10-K for the year ended December 31, 2021 as supplemented by our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022. Renal Transplant Rejection Dosed the second patient in the Phase 1/2 STEADFAST study; progressed clinical activities in preparation for patient three. Total operating expenses on a GAAP basis for the third quarter ended September 30, 2022 were $81.3 million, compared to $77.0 million for the same period in 2021. Forward-looking statements contained in this announcement are made as of this date, and we undertake no duty to update such information except as required under applicable law. We expect to present additional clinical updates from the STAAR study, including the first data from the expansion cohort, in the first half of 2023. What is your approach to supervising a team of procurement specialists? Conference Call to Discuss Second Quarter 2022 Results. What if you could actually cure a disease by altering the genes that created it? I interviewed at Sangamo Therapeutics in Jan 2021. Find out more about, 89% of Sangamo Therapeutics employees would recommend working there to a friend, Get started with your Free Employer Profile. Changes wont be saved until you sign up for an Enhanced Profile subscription. Super friendly working environment and very nice people. Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results News Release Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated -Gal A Enzyme Activity in Nine Patients News Release Interview experience. We made meaningful progress advancing our clinical-stage programs in the second quarter, said Sandy Macrae, Chief Executive Officer of Sangamo. Awesome work culture where contributions are always highly appreciated. The process took 4 weeks. Based on 2 interviews. To learn more, visit www.sangamo.com and connect with us on LinkedIn and Twitter. I applied through a recruiter. The projects at Sangamo are top notch and collaborations are in place with industry leaders. I applied online. Sangamo is one of the few companies pursuing programs across the spectrum of genomic medicine. Sangamo Therapeutics, Inc.(Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and third quarter 2022 financial results. Was told I was a candidate in the running but they never got back to me and never responded to multiple calls or emails, Anonymous Interview Candidate in San Francisco, CA, I applied online. Under the general direction of the EHS Director, this role will have operational responsibility for EHS support to labs, facilities and manufacturing and shall assist with planning, establishing, implementing, and maintaining a variety of occupational health, safety, and . There are no open jobs at Sangamo Therapeutics, Inc. currently. Sangamo Therapeutics has an overall rating of 4.2 out of 5, based on over 55 reviews left anonymously by employees. Get started with your Free Employer Profile. I interviewed at Sangamo Therapeutics in Aug 2020, Nice set of interviews and great questions. Progressed clinical activities in preparation for the third patient. Common stages of the interview process at Sangamo Therapeutics according to 17 Glassdoor interviews include: Find a Great First Job to Jumpstart Your Career, Stand Out From the Crowd With the Perfect Cover Letter, How to Prepare for Your Interview and Land the Job. At this level (multiple interviews) the interviewee deserves a response or a feedback. This is the Sangamo Therapeutics company profile. The Sangamo management team will discuss these results on a conference call today, Thursday November 3, 2022, at 4:30 p.m. Eastern Time. We expect to present updated data from the Phase 1/2 ALTA study via a poster presentation at the ASH Annual Meeting in December. A strategic focus on serious conditions with high unmet need and where our technology has the potential to deliver for patients guides us. Guided by Science. Tell me about yourself? Morale was specifically low and retention was really bad at the company when I left in Dec 2021 as management had become quite manipulative trying to find any reasons not to give people raises. Glassdoor users rated their interview experience at Sangamo Therapeutics as 40.0% positive with a difficulty rating score of 2.86 out of 5 (where 5 is the highest level of difficulty). Due to the split at Richmond and Brisbane, there was confusion on which site to interview. Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. We completed the transition of Sanofis rights and obligations under the collaboration developing BIVV003, formerly known as. Duties of the advertised position and the involved project. Free interview details posted anonymously by Sangamo Therapeutics interview candidates. Over 50% of the patients have been enrolled in the Phase 3 AFFINE trial. Coupled with strong advances in our preclinical pipeline, we believe this progress positions us well to advance the development of potentially transformational genomic medicines for patients in need and to generate long-term value for our shareholders.. Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. I interviewed at Sangamo Therapeutics in Jul 2021. View the full . Based on 2 interviews. Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. We plan to provide guidance on timing for dosing for the third patient once the kidney transplant has been scheduled. Working in the company was very fun, I learned a lot about the technology that the company uses and about the different methodologies and techniques Sangamo has. Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time. However, after the last interview I haven't heard back from them. Sangamo Therapeutics Inc (NASDAQ: SGMO) announced updated preliminary data as of October 20, 2022, the cutoff date from the Phase 1/2 STAAR study of isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for Fabry disease. I interviewed at Sangamo Therapeutics in Jul 2021. We continue to actively prepare for a potential pivotal Phase 3 trial. They said they get tested for Sars once a week, which is great too. I interviewed at Sangamo Therapeutics. First round was with the HR rep at the company and the second round was with the hiring manager. Since the beginning of the second quarter, we have raised approximately $43.1 million in net proceeds under our previously announced at the market offering program. Sickle cell disease Completed transition of program back to Sangamo; advanced manufacturing activities in anticipation of dosing in Q3; Phase 3 planning progresses. Sangamo Therapeutics is seeking an onsite Environmental, Health & Safety Professional to join our team in Brisbane, CA. Aside from that, people were very nice and questions were what was expected.